Compare GOVX & TNON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOVX | TNON |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.8M |
| IPO Year | 1996 | 2021 |
| Metric | GOVX | TNON |
|---|---|---|
| Price | $0.28 | $2.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.00 | ★ $44.38 |
| AVG Volume (30 Days) | 814.4K | ★ 915.4K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 84.90 |
| EPS | ★ N/A | N/A |
| Revenue | $2,489,145.00 | ★ $3,944,000.00 |
| Revenue This Year | N/A | $46.86 |
| Revenue Next Year | N/A | $63.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.35 |
| 52 Week Low | $0.27 | $2.40 |
| 52 Week High | $157.50 | $50.40 |
| Indicator | GOVX | TNON |
|---|---|---|
| Relative Strength Index (RSI) | 23.04 | 40.23 |
| Support Level | N/A | $2.54 |
| Resistance Level | $0.46 | $4.18 |
| Average True Range (ATR) | 0.04 | 0.24 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 7.65 | 22.19 |
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.